Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe study record includes metadata updates: a new last update date, revised estimated study completion dates, and removal of the old registry identifier, with other historical dates added. These changes update timeline and registry references but do not modify treatment, eligibility, or participating locations.SummaryDifference0.4%

- Check13 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, indicating a minor platform update. This change does not affect study content, eligibility, or outcomes.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This signals a minor update to the page version rather than a change to the study content.SummaryDifference0.1%

- Check35 days agoChange DetectedRecruitment status is updated to indicate enrollment is closed, with the addition of guidance sections for reading the study record and joining a study; the page also shows an updated Intervention/Treatment header and a new revision note (Revision: v3.6.0).SummaryDifference0.4%

- Check42 days agoChange DetectedThe page revision updated from v3.5.4 to v3.5.5, indicating a small patch or update to the page's software or rendering. The overall content and purpose of the study page appear unchanged.SummaryDifference0.1%

- Check63 days agoChange DetectedThe study record shows a new revision version (v3.5.4) replacing the previous v3.5.3. This indicates a backend or documentation update, and no study details appear to be altered.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.